Comparative Pharmacology
Head-to-head clinical analysis: ENOVID versus JUNEL FE 1 5 30.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ENOVID versus JUNEL FE 1 5 30.
ENOVID vs JUNEL FE 1.5/30
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination estrogen-progestin contraceptive; suppresses gonadotropins (LH, FSH) via negative feedback on hypothalamic-pituitary axis, inhibiting ovulation; increases viscosity of cervical mucus and alters endometrial lining to impair implantation.
Combination estrogen-progestin contraceptive; suppresses gonadotropin release (FSH, LH) via negative feedback, inhibiting ovulation, increasing cervical mucus viscosity, and altering endometrial receptivity.
Oral, 5 mg daily for 20 days starting on day 5 of menstrual cycle for ovulation inhibition; for endometriosis, 5 mg daily for 15 days increasing to 10 mg daily if breakthrough bleeding occurs.
One tablet orally once daily, each tablet containing norethindrone acetate 1.5 mg and ethinyl estradiol 30 mcg, taken at the same time each day for 21 days followed by 7 days of placebo (iron tablets).
None Documented
None Documented
Norethynodrel: 5-12 hours; mestranol: 7-20 hours. Terminal half-life of ethinyl estradiol from mestranol conversion: 10-30 hours. Clinical context: steady-state achieved after 3-5 half-lives (3-5 days).
Norethindrone: 6-12 hours (terminal, multidose); ethinyl estradiol: 12-18 hours (terminal). Clinical context: Steady-state achieved within 5-7 days; missed doses may reduce contraceptive efficacy.
Renal (30-50% as metabolites, <5% unchanged) and fecal (40-60% via bile, mostly as glucuronide conjugates).
Renal: 30-50% (norethindrone metabolites), 20-40% (ethinyl estradiol metabolites); biliary/fecal: 20-30% (norethindrone), 30-50% (ethinyl estradiol). Conjugated metabolites excreted in bile and undergo enterohepatic recirculation.
Category C
Category C
Oral Contraceptive
Oral Contraceptive